We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




LC-MS/MS Assay Directly Detects Urinary Bacteria

By LabMedica International staff writers
Posted on 30 Oct 2019
Print article
Image: The Q Exactive HF-X hybrid quadrupole mass spectrometer (Photo courtesy of Thermo Fisher Scientific).
Image: The Q Exactive HF-X hybrid quadrupole mass spectrometer (Photo courtesy of Thermo Fisher Scientific).
Fast identification of microbial species in clinical samples is essential to provide an appropriate anti-biotherapy to the patient and reduce the prescription of broad-spectrum antimicrobials leading to anti-bioresistances.

Matrix-assisted laser desorption/ionization – time of flight-mass spectrometry (MALDI-TOF-MS) technology has become a tool of choice for microbial identification, but has several drawbacks as it requires a long step of bacterial culture prior to analysis (24 hours), has a low specificity and is not quantitative.

Scientists at the Centre Hospitalier Universitaire de Québec (Québec, QC, Canada) and their colleagues developed a new strategy for identifying bacterial species in urine using specific liquid chromatography–mass spectrometry (LC-MS/MS) peptidic signatures. The team combined several mass spectrometry techniques to develop their assay, starting with shotgun mass spectrometry assays of pure bacterial colonies to develop mass spectral libraries for use in subsequent data-independent acquisition (DIA) assays. They used those DIA assays to detect bacterial peptides in urine samples, quantifying 31,000 peptides from 190 samples containing 15 bacterial species that cause 84% of all urinary tract infections (UTIs).

The sceintists tested these targeted assays in urine samples inoculated with the four most commonly found causes of UTIs (Escherichia coli, Streptococcus agalactiae, Enterococcus faecalis, and Klebsiella pneumonia) at five different concentrations running the experiments with 90-minute LC gradients on a Thermo Fisher Scientific Orbitrap Fusion. They also ran the samples on a Thermo Fisher Q Exactive HF-X using a 30-minute LC gradient. The assays showed 100% accuracy in all inoculations at concentrations above the standard clinical threshold and 97% accuracy overall.

The scientists also compared their direct detection approach to a standard MALDI-TOF workflow, finding that in a set of 27 patients, the two methods agreed on 19 of the samples (seven of which were not infected and nine of which were infected with E. coli), while disagreeing on eight samples, seven of which the MALDI-TOF method identified as infected while the LC-MS/MS approach identified as not infected, though these seven were identified by the MALDI-TOF at the genus, but not species level.

The authors concluded that their work demonstrates the efficiency of the method for the rapid and specific identification of the bacterial species causing UTI and could be extended in the future to other biological specimens and to bacteria having specific virulence or resistance factors. The study was published on October 4, 2019, in the journal Molecular & Cellular Proteomics.

Related Links:
Centre Hospitalier Universitaire de Québec

New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
C-Reactive Protein Assay
OneStep C-Reactive Protein (CRP) RapiCard InstaTest
New
Herpes Simplex Virus ELISA
HSV 2 IgG – ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.